Supplementary figure S1 from Low-dose Paclitaxel with Pembrolizumab Enhances Clinical and Immunologic Responses in Platinum-refractory Urothelial Carcinoma
The study design illustrated here shows the treatment phase with combination paclitaxel and pembrolizumab, followed by maintenance pembrolizumab if disease is stable or improved after 6 months of combination therapy.
No Comments.